Role of GLP-1 Receptor Agonists in Gastrointestinal Motility Disorders

Mechanism of Action on GI Motility

• GLP-1 receptor agonists delay gastric emptying primarily through vagal nerve-mediated pathways, with receptors located on the myenteric plexus activating nitrergic and cyclic adenosine monophosphate pathways to inhibit vagal activity on the gut 2
• GLP-1 receptor activation leads to multiple gastrointestinal effects: reduced phasic gastric contractions, delayed gastric emptying, reduced gastric acid secretion, increased fasting volumes, and increased postprandial gastric volumes 2, 3
• The motility effects are more pronounced in individuals with normal or rapid baseline gastric emptying compared to those with already delayed emptying 2

Effects on Different Segments of the GI Tract

• No relevant cited facts available for this section

Differences Between GLP-1 Receptor Agonist Formulations

• Short-acting GLP-1 receptor agonists (like exenatide) have more pronounced effects on delaying gastric emptying than long-acting formulations 2
• The effects on gastric emptying diminish with continuous exposure (tachyphylaxis), suggesting adaptation of the autonomic nervous system to continuous GLP-1 administration 2
• Acute and intermittent infusions of GLP-1 receptor agonists have more pronounced effects on delaying gastric emptying than continuous infusions 2

Clinical Applications in Motility Disorders

• GLP-1 receptor agonists may be particularly beneficial in conditions characterized by accelerated gastric emptying, as their delaying effect is more pronounced in patients with rapid baseline emptying 2
• The delay in gastric emptying contributes significantly to the glucose-lowering effects of these medications by slowing nutrient absorption 3

Important Clinical Considerations and Cautions

• These medications should be used with caution in patients with pre-existing gastroparesis or delayed gastric emptying, as they may exacerbate symptoms 4
• The effects of GLP-1 receptor agonists on gastric emptying are not present in patients who have had a vagotomy, indicating the vagal-dependent mechanism 2

Management of GLP-1 RA-Related Motility Effects

• Start GLP-1 receptor agonists at low doses and titrate upward slowly to minimize gastrointestinal side effects 4
• Reducing meal size and avoiding high-fat diets can help manage GI symptoms 4
• For patients with gastrointestinal symptoms, consider evaluation with appropriate motility testing such as scintigraphy (the gold standard) rather than less reliable methods like paracetamol absorption tests 2